Published in final edited form as:

Int J Stroke. 2010 June ; 5(3): 163–166. doi:10.1111/j.1747-4949.2010.00425.x.

Lack of Association Between Hyperglycemia at Arrival and Clinical Outcomes in Acute Stroke Patients Treated with Tissue Plasminogen Activator

William J. Meurer, MD, MS^{1,2}, Phillip A. Scott, MD¹, Angela F. Caveney, PhD³, Jennifer J. Majersik, MD, MS², Shirley M. Frederiksen, BSN, MS¹, Annette Sandretto, MSN¹, Ann B. Holden, BSN¹, and Robert Silbergleit, MD¹

¹Department of Emergency Medicine, University of Michigan, Ann Arbor, MI

²Department of Neurology, University of Michigan, Ann Arbor, MI

³Department of Psychiatry and Neuropsychology, University of Michigan, Ann Arbor, MI

⁴Department of Neurology, University of Utah, Salt Lake City, Utah

Abstract

Rationale—Hyperglycemia is associated with adverse outcomes in some studies of acute ischemic stroke.

Aims—We hypothesized that in thrombolytic treated stroke patients, hyperglycemia would be independently associated with hemorrhagic transformation and unfavorable outcome.

Design—Consecutive rt-PA-treated acute ischemic stroke patients presenting to four emergency departments were analyzed. Associations of initial blood glucose and survival to hospital discharge, symptomatic intracerebral hemorrhage (sICH), any form of intracerebral hemorrhage (ICH), and disability at hospital discharge were determined. Potentially confounding factors of age, NIHSS, and smoking were analyzed by univariate logistic regression and those with $p < 0.3$ included in the multivariate model.

Study Outcome—In 268 patients, initial glucose values ranged from 62–507 mg/dL (mean 131). Elevated glucose at arrival was not significantly associated with any adverse clinical outcomes. A trend toward higher mortality in hyperglycemic patients (OR 1.71 per 100 mg/dL increase in glucose, 95% C.I. 0.92–3.13, $p=0.08$) was seen, but is of unclear significance, and was not corroborated by effects on discharge disability, sICH or ICH.

Conclusions—Thrombolytic treated stroke patients with hyperglycemia at presentation did not have significantly worse outcomes than others in this cohort. These data fail to confirm previously described associations seen in similarly sized studies. Further study of these associations and their magnitude are necessary to better define the relationship between serum glucose and outcome in thrombolytic treated acute ischemic stroke.

WJM conceived the study. PAS, SRF and RS supervised the conduct of the study and data collection. AFC, SMF, ABH, and AS all collected data. PAS and SMF participated in management and quality control of the data. PAS and RS provided advice on the study design. JJM performed critical review of the manuscript. WJM analyzed the data. WJM drafted the manuscript and all authors contributed substantially to its revision. WJM takes responsibility for the paper as a whole.

Presented in Abstract Form at the Annual Meeting of The Society For Academic Emergency Medicine, Chicago, IL May 2007; the Emergency Medicine Residents Association of Michigan Research Forum, Lansing, MI April 2007; and the Mediterranean Emergency Medicine Conference, Sorrento, Italy September 2007

Keywords

acute ischemic stroke; thrombolysis; hyperglycemia; outcomes; observational study

Introduction

Hyperglycemia is common in the acute phase of ischemic stroke and has been associated with adverse outcomes, specifically increased risk of hemorrhagic transformation, disability, increased health care costs and death in some studies^{1,2}. In some experimental stroke models, hyperglycemia increases reperfusion injury and infarct related hemorrhage^{3, 4}. It also has been shown to increase infarct volume in some human and animal studies^{5,6}. In studies examining thrombolysis in ST-segment elevation myocardial infarction, hyperglycemia diminishes the resolution of ST-segment elevation, suggesting hyperglycemia attenuates the efficacy of thrombolysis.⁷ Only a small number of studies have examined the outcomes and complications of thrombolytic treated stroke patients with hyperglycemia.^{8–10}

Previous trials of intensive in-hospital control of glucose in stroke patients have been completed and others are ongoing.^{11–13} Recent trials of glucose lowering in stroke and intensive care have failed to demonstrate improved outcomes in patients with tight glycemic control, illustrating the need for additional observational data on the relationship between glucose and stroke, especially in thrombolytic treated patients.^{14, 15} The current acute stroke management guideline recommends treatment of hyperglycemia and suggests use of insulin when glucose levels are in excess of 140 mg/dL, but does not specifically address or advocate glucose lowering before thrombolysis.¹⁶ Thrombolytic treatment guidelines in existence during the time period examined in this study recommended withholding tPA therapy when patients have very high glucose levels (>400 mg/dL) due to concerns of treating patients with clinical presentations mimicking acute ischemic stroke.¹⁷

In this analysis, we hypothesized that in rt-PA-treated stroke patients, hyperglycemia at presentation would be an independent risk factor for cerebral hemorrhage and for unfavorable clinical outcome. We determined the odds ratios for poor outcomes related to blood glucose on presentation in a large cohort of intravenous rt-PA treated acute stroke patients.

Methods

Consecutive stroke patients treated with intravenous (IV) rt-PA between January 1, 1996 and January 1, 2005 were identified from four emergency departments (EDs) serving a contiguous, four county region in Michigan. The Institutional Review Board from each site approved the study prior to data collection. Four independent, trained study personnel completed all reviews using the paper chart and/or electronic medical record. A standardized data collection form was used. Cases were identified using four deliberately redundant methods: 1) discharge diagnoses containing any International Classified Diseases Version 9 (ICD-9) Code for cerebrovascular disease (430–437; 997.02) plus a procedure code for thrombolysis (99.10 or CPT codes 37195 or 37201); 2) review of hospital pharmacy logs of rt-PA use in ED; 3) review of site-specific stroke registries maintained for quality improvement purposes; and 4) through review of Paul Coverdell National Acute Stroke Registry Data (5/2002 – 11/2002) for two of the hospitals.

Four outcomes were studied: survival to hospital discharge, symptomatic intracerebral hemorrhage (sICH), the presence of any intracerebral hemorrhage (ICH), and disability at

hospital discharge as determined by modified Rankin Score (mRS) calculated from chart review using previously reported methodology.¹⁸ All intracerebral hemorrhages were classified by two independent radiologists using the definitions described in the European Cooperative Stroke Study (ECASS).¹⁹ Symptomatic ICH was defined as parenchymal hemorrhage type 2 as outlined in ECASS. Disagreements were adjudicated by a third radiologist. Patients with a pre-stroke modified Rankin (mRS) score greater than 1 were excluded from the outcome analysis of disability. These patients had pre-existing disability and would not be expected to lose that disability after suffering from a stroke. Post-stroke disability was defined as a mRS of 2 or greater at hospital discharge. The data were analyzed using SPSS software (SPSS, Inc. Chicago, Illinois).

The associations between outcomes and initial glucose were determined by logistic regression. Pre-existing diagnosis of diabetes was substituted for glucose in a subsequent analysis but was not included in the initial model due to the strong interaction with glucose. Potentially confounding factors of age, NIHSS, and smoking within last year were analyzed by univariate logistic regression and those with $p < 0.3$ were included in a multivariate model. These variables were pre-specified and were chosen for this analysis as the only pre-treatment factors ($p < 0.1$) from the NINDS rt-PA trial which were predictive of symptomatic hemorrhage.^{20, 21} The same logistic regression methodology as above was also used separately on the patients with and without pre-existing diabetes.

The odds ratio (OR) for each adverse outcome per 100 mg/dL increment in initial glucose was calculated with 95% confidence intervals (CI). Linear regression was performed between the baseline National Institutes of Health Stroke Scale (NIHSS) and the presenting glucose to determine whether an association between these variables existed.

Results

Two hundred seventy-three consecutive tPA-treated acute stroke patients were studied. Initial blood glucose measurements obtained in the ED were documented for 268 patients; five patients with unknown glucose were excluded. Only one patient had documented treatment with insulin in the emergency department (initial glucose 206 mg/dL).

Initial glucose ranged from 62–507 mg/dL with a mean of 131. In hospital mortality was 12.8%. Symptomatic ICH occurred in 6.6% of cases and any ICH in 9.9%. Smoking within the past year, baseline NIHSS, and age were significant predictors on univariate analyses and were included all of the final models examining the relationship between initial glucose and clinical outcomes. The associations between elevated glucose at arrival and disability, death, ICH and sICH in tPA-treated stroke patients were weak and did not reach statistical significance, though there was a trend towards significance in the association between glucose and death (Table 1). Trends were stronger for an association between glucose and death than with discharge disability, sICH or ICH. When the analysis was repeated in patients with and without a prior diagnosis of diabetes, the associations between glucose and the study outcomes also did not achieve statistical significance. Outcomes for patients at increasing glucose levels are presented in Figures 1 and 2 (Three outlying patients with glucose greater than 300 mg/dL are not included in these figures). The correlation between baseline NIHSS and presenting glucose was minimal (Adjusted $R^2 = 0.002$). This relationship is plotted in the appendix.

When diabetes was substituted for glucose in the analysis, a significant association with the outcomes still was not seen (Table 2). There was a trend towards a decreased likelihood of both ICH and sICH, but higher death rates in patients with diabetes. Tobacco use was not significantly associated with any of the outcomes.

Discussion

One limitation of this study is the sample size. Although not statistically significant, some of the odds ratios found in this study are of magnitudes that conceivably may have achieved significance with a larger sample. Another limitation is that glucose at presentation was lower in this cohort than what had been observed in prior studies of stroke thrombolysis.^{19, 22} Hyperglycemia was less common both in patients with and without known diabetes compared to other studies, likely making adverse effects harder to identify. In addition, trends in the glucose values over the course of the hospitalization were not collected. In addition, we had a relatively small number of events and this limited the number of covariates that could be included in the logistic regression model. Last, data on insulin use outside of the emergency department was not collected which ideally would be controlled for since post-tPA control of hyperglycemia may affect the post-tPA clinical outcomes and hemorrhage rates.

Two prior studies have specifically examined the relationship between glucose level and stroke outcomes in thrombolytic-treated or eligible patients in the NINDS tPA stroke trial.^{1, 20} An analysis of the treatment group alone, in which glucose was treated as a dichotomous variable (with a cutoff of 300 mg/dL), showed no statistical difference in outcomes.²⁰ However, a more recent analysis that included both treatment and control groups, examined glucose as a continuous variable and concluded that hyperglycemia on presentation was associated with significantly lower odds of favorable outcome and significantly higher odds for sICH, regardless of tPA treatment.¹

Our study did not confirm a significant association between hyperglycemia and outcomes, either because there is no such association, or because the association is too small to be detected in this analysis of 268 patients. Hyperglycemia on presentation in acute ischemic stroke patients treated with tPA was not significantly associated with mortality, disability, ICH, or sICH. Associations too small to be detected with this sample size cannot be ruled out, however, prior reports have linked hyperglycemia to adverse outcomes in similarly sized or smaller cohorts.^{8, 21, 23} These data do not disprove the potential adverse effects of sustained hyperglycemia. In addition, these data do not suggest any significant attenuation of thrombolytic efficacy related to early hyperglycemia at presentation within three hours of stroke onset. A larger analysis of pooled trial data may be more revealing, and may assist in the design of a hyper-acute pre-hospital or emergency department glucose lowering therapy trial in acute stroke patients who receive tPA. Further studies are necessary to better define the relationship between serum glucose and outcome in tPA treated acute ischemic stroke.

Acknowledgments

This work is supported by: NIH / NINDS Grant R01 NS050372; Michigan Department of Community Health Grant # N007059

References

1. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. *Neurology*. 2002; 59:669–74. [PubMed: 12221155]
2. Levetan CS. Effect of hyperglycemia on stroke outcomes. *Endocr Pract*. 2004; 10:34–9. [PubMed: 15251638]
3. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. *Stroke*. 1989; 20:1707–15. [PubMed: 2595734]
4. Broderick JP, Hagen T, Brott T, Tomsick T. Hyperglycemia and hemorrhagic transformation of cerebral infarcts. *Stroke*. 1995; 26:484–7. [PubMed: 7886729]

5. Baird TA, Parsons MW, Phan T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. *Stroke*. 2003; 34:2208–14. [PubMed: 12893952]
6. Roos MW. Effects of hyperglycemia on small cerebral infarctions in awake rabbits. *Ups J Med Sci*. 1999; 104:145–61. [PubMed: 10422217]
7. L'Huillier I, Zeller M, Mock L, et al. Relation of hyperglycemia to ST-segment resolution after reperfusion for acute myocardial infarction (from Observatoire des Infarctus de Cote-d'Or Survey [RICO]). *Am J Cardiol*. 2006; 98:167–71. [PubMed: 16828586]
8. Alvarez-Sabin J, Molina CA, Ribo M, et al. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. *Stroke*. 2004; 35:2493–8. [PubMed: 15472110]
9. Christensen H. Hyperglycaemia in patients after intravenous thrombolysis. *Cerebrovasc Dis*. 2003; 15:154–5. [PubMed: 12499730]
10. Martini SR, Hill MD, Alexandrov AV, et al. Outcome in hyperglycemic stroke with ultrasound-augmented thrombolytic therapy. *Neurology*. 2006; 67:700–2. [PubMed: 16924029]
11. Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. *Stroke*. 2006; 37:267–73. [PubMed: 16306459]
12. Bruno A, Saha C, Williams LS, et al. IV insulin during acute cerebral infarction in diabetic patients. *Neurology*. 2004; 62:1441–2. [PubMed: 15111697]
13. Scott JF, Robinson GM, French JM, et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). *Stroke*. 1999; 30:793–9. [PubMed: 10187881]
14. The NICE-SUGAR Study Investigators. Intensive versus Conventional Glucose Control in Critically Ill Patients. *NEJM*. 2009; 360:1283–97. [PubMed: 19318384]
15. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). *Lancet Neurol*. 2007; 6:397–406. [PubMed: 17434094]
16. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke*. 2007; 38:1655–1711. [PubMed: 17431204]
17. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients With Acute Ischemic Stroke: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. *Circulation*. 1996; 94:1167–74. [PubMed: 8790069]
18. Sandretto A, M. Scott PA, Caveney AF, et al. Precision of Retrospective Assignment of Modified Rankin Scale (mRS) in tPA-treated Ischemic Stroke Patients by Stroke Coordinators (Abstract). *Stroke*. 2007; 38:453–607.
19. Hacke WW, Kaste MM, Fieschi CC, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA*. 1995; 274:1017–25. [PubMed: 7563451]
20. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. *Stroke*. 1997; 28:2109–18. [PubMed: 9368550]
21. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. *Stroke*. 1999; 30:34–39. [PubMed: 9880385]
22. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *NEJM*. 1995; 333:1581–7. [PubMed: 7477192]

23. Els T, Klisch J, Orszagh M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. *Cerebrovasc Dis.* 2002; 13:89–94. [PubMed: 11867881]

Figure 1.

Distribution of initial glucose for subjects with and without symptomatic ICH within 36 hours of tPA treatment.

sICH: Symptomatic intracerebral hemorrhage. Distribution of glucose at presentation in study in mg/dL. Four cases presented with glucose greater than 300 mg/dL and none had sICH within 36 hours of treatment.

Figure 2.

Level of disability at discharge by initial glucose.

mRS: modified Rankin Scale. Distribution of glucose measurements at presentation measured in mg/dL by level of disability is depicted. One patient with glucose of 312 mg/dL had mRS of two, one patient with glucose of 325 mg/dL had mRS of four. Two patients died in the hospital with glucoses of 323 and 507 mg/dL.

Table 1

Relationship of increasing glucose to outcomes by multivariate analysis controlling for age, smoking within past year, and stroke severity.

Outcome	Adjusted OR per 100 mg/dL increase in glucose	95% CI	P
Death	1.71	0.92–3.13	0.08
Disability	2.00	0.78–5.09	0.15
sICH	1.16	0.43–3.13	0.70
any ICH	1.19	0.53–2.68	0.68

OR: odds ratio; CI: confidence interval

Table 2

Relationship of diabetes by history to outcomes by multivariate analysis controlling for age, smoking within past year, and stroke severity.

Outcome	Adjusted OR for diabetes versus non diabetics	95% CI	P
Death	1.99	0.89–4.46	0.094
Disability	2.3	0.733–7.243	0.153
sICH	0.33	0.072–1.50	0.15
any ICH	0.34	0.0968–1.2011	0.094

OR: odds ratio; CI: confidence interval